Nuclear Medicine and Biology
Volume 35, Issue 6 , Pages 645-653 , August 2008

The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of 111In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin)

  • Bart Cornelissen

      Affiliations

    • Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada M5S 3M2
    • ,
  • Kristin McLarty

      Affiliations

    • Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada M5S 3M2
    • ,
  • Veerle Kersemans

      Affiliations

    • Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada M5S 3M2
    • ,
  • Raymond M. Reilly

      Affiliations

    • Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada M5S 3M2
    • Department of Medical Imaging, University of Toronto, Toronto, ON, Canada M5S 3M2
    • Toronto General Research Institute, University Health Network Toronto, Toronto, ON, Canada M5S 3M2
    • Corresponding Author InformationCorresponding author. Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada M5S 3M2. Tel.: +1 416 946 5522; fax: +1 416 978 8511.

Received 9 April 2008 ,Revised 24 May 2008 ,Accepted 27 May 2008.

References 

  1. Baselga J. Clinical trials of Herceptin (trastuzumab). Eur J Cancer. 2001;37:S18–S24
  2. Tokunaga E, Oki E, Kojiro N, Koga T, Egashira A, et al. Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol. 2006;11:199–208
  3. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001;93:1852–1871
  4. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992;24:85–95
  5. Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer. 2004;108:334–341
  6. Burger A, Leyland-Jones B, Banerjee K, Spyropoulos DD, Seth AK. Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. Eur J Cancer. 2005;41:1515–1527
  7. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;351:1393–1396
  8. Resnik JL, Reichart DB, Huey K, Webster NJG, Seely BL. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res. 1998;58:1159–1164
  9. Shin A, Ren Z, Shu O, Cai Q, Gao YT, Zheng W. Expression patterns of insulin-like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survival. Breast Cancer Res Treat. 2007;105:55–61
  10. King R, Wells JR, Krieg P, Snoswell N, Brazier J, Bagley CJ, et al. Production and characterization of recombinant insulin-like growth factor-I (IGF-I) and potent analogues of IGF-I, with Gly or Arg substituted for Glu3, following their expression in Escherichia coli as fusion proteins. J Mol Endocrinol. 1992;8:29–41
  11. LeRoith D, Werner H, Faria TN, Kato H, Adamo M, Roberts CT. Insulin-like growth factors. Ann N Y Acad Sci. 1993;692:22–32
  12. Wen B, Deutsch E, Marangoni E, Frascona V, Maggiorella L, Abdulkarim B, et al. Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Br J Cancer. 2001;85:2017–2021
  13. DuManoir J, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res. 2006;12:904–916
  14. Reilly R, Lee N, Houle S, Law J, Marks A. In vitro stability of EDTA and DTPA immunoconjugates of monoclonal antibody 2G3 labeled with indium-111. Int J Rad Appl Instrum [A]. 1992;43:961–967
  15. Tang Y, Wang J, Scollard DA, Mondal H, Holloway C, Kahn HJ, et al. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using [111In]-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol. 2005;32:51–58
  16. Costantini D, Chan C, Cai Z, Vallis KA, Reilly RM. 111In-trastuzumab (Herceptin) modified with nuclear localizing sequences (NLS): A novel Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med. 2007;48:1357–1368
  17. Sun BF, Kobayashi H, Le N, Yoo TM, Drumm D, Paik CH, et al. Effects of insulinlike growth factor binding proteins on insulinlike growth factor-1 biodistribution in tumor-bearing nude mice. J Nucl Med. 2000;41:318–326
  18. Fabry M. Synthesis and characterization of photoreactive insulin-like growth factor 1 derivatives for receptor analysis. Bioconj Chem. 1999;10:200–205
  19. Sitar T, Popowicz GM, Siwanowicz I, Huber R, Holak TA. Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins. Proc Natl Acad Sci U S A. 2006;103:13028–13033
  20. Reilly RM, Sandhu J, Alvarez-Diez TM, Gallinger S, Kirsh J, Stern H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet. 1995;28:126–142
  21. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25:201–212
  22. Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol. 2001;12(Suppl 1):S35–S41
  23. Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J, et al. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates Herceptin activity in vivo. Cancer Res. 2006;66:7245–7252
  24. Sachdev D, Yee D. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J Mammary Gland Biol Neoplasia. 2006;11:27–39
  25. Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res. 2007;13:4291–4299

☆ This study was supported by grants from the Ontario Cancer Research Network (No. 03-NOV-0428; One Millimetre Cancer Challenge Imaging Platform) with funds from the Province of Ontario. Kristin McLarty was supported by a Canadian Institutes of Health Research (CIHR) Excellence in Radiation Research (EIRR) fellowship. Veerle Kersemans was supported by a Wyeth-CIHR postdoctoral fellowship.

PII: S0969-8051(08)00118-2

doi: 10.1016/j.nucmedbio.2008.05.010

Nuclear Medicine and Biology
Volume 35, Issue 6 , Pages 645-653 , August 2008

Article Tools

* Image Usage & Resolution